Torrent Pharmaceuticals Ltd (TORNTPHARM) Q1 FY27 Earnings Call: Revenue Surges 55% on JB Merger, Organic Growth Outpaces IPM

Torrent Pharmaceuticals Ltd held its Q1 FY27 earnings call on July 30, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Consolidated Revenue Surges 55% on JB Merger & Base Business Momentum

• Consolidated revenue of Rs.4,921 Cr — up 55% YoY in Q1 FY 2026-2027, driven by the JB Pharma merger (effective 8 July 2026) and strong organic growth.
• Operating EBITDA of Rs.1,664 Cr — up 61% YoY, with margin expanding to 33.8% from 32.8% in the prior-year quarter.
• Torrent base business (ex-JB) grew 17% — contributed Rs.1,240 Cr EBITDA (up 20%, margin 33.3%) in Q1 FY 2026-2027.
• JB Pharma contributed Rs.1,201 Cr revenue — up 10% YoY, with EBITDA of Rs.424 Cr and margin of 35.3%, an improvement of >6 percentage points.
• Net debt to EBITDA stood at 2.07x — on a combined company basis as of Q1 FY 2026-2027.

Organic Growth of 19% Outpaces IPM; Cardiac Market Now #1

• India base business grew 19% in Q1 FY 2026-2027 — versus IPN (industry) growth of 12% (per AIOCD PharmaTrac data); volume contributed 5.1%, price 7.7%, and new products 6%.
• Combined Torrent+JB ranked #1 in the cardiac market — the largest segment in the Indian pharmaceutical market.
• 28 brands now above Rs.100 Cr — top 10 brands grew 20%+ in Q1 FY 2026-2027, driven by field force expansion over the last 2-3 years.
• Curatio portfolio grew 34% — supported by OTC ad spends and field force expansion; further expansion planned for FY 2026-2027.
• Combined field force of 9,400 — base 7,200 plus JB 2,200; combined PCPM > Rs.10 lakhs; JB attrition fell to 16% in June 2026 (from ~30% pre-acquisition).
• Field force expected to reduce to ~9,000 in Q2 FY 2026-2027 — as integration proceeds; end of FY 2026-2027 may be slightly lower, with no fresh expansion planned.
• Volume uptick is a one-quarter phenomenon — management called for 2-3 more quarters (through Q3-Q4 FY 2026-2027) to assess sustainability of the prescription growth trend.

Cost Synergies Tracking Ahead of Plan; Revenue Synergies from FY 2027-2028

• First-year cost synergy target of Rs.90 Cr for FY 2026-2027 — tracking above Rs.100 Cr, though management refrains from updating the exact target due to potential top-line changes in some territories.
• Merger approved in July 2026, six months earlier than anticipated — allowing integration to start immediately; cost synergy realization is expected to be faster than the original three-year plan.
• JB EBITDA margins reached 35% in Q1 FY 2026-2027 — improvement largely driven by cost synergies implemented sooner than expected; margins expected to improve incrementally each quarter.
• Revenue synergies not expected before FY 2027-2028 — cross-sell opportunities in cardiac and gastro will be addressed after full integration; management will provide guidance after the combined entity settles.
• Transition impact on brand performance in Q2 and Q3 FY 2026-2027 — as JB Pharma brands are transferred to Torrent's field force, with normalization expected by Q4 FY 2026-2027.
• Manufacturing synergies are in a second phase — not included in the current cost synergy targets.
• Management will wait at least another 12-18 months (from Q1 FY 2026-2027 call date) to assess the JB acquisition — before considering new M&A, with a preference for Indian acquisitions and a target not to exceed 3x-3.5x net debt to EBITDA.

Brazil and US Deliver Strong Growth; Germany Remains a Drag

• Brazil revenues rose 27% in Q1 FY 2026-2027 — constant currency growth of 19% per IQVIA (market growth 4%), with generics contributing ~22% of sales; one-time channel inventory correction reduced reported growth by ~15-18%.
• Normalized Brazil growth expected to return to mid-teens in Q2 FY 2026-2027 — after the channel inventory correction.
• US business grew 36% in Q1 FY 2026-2027 — constant currency revenues of $44 Mn, up 23% from new launches and one-time opportunities; Torrent expects to be a profitable entity in the US for FY 2026-2027, a change from the last 5 years.
• 17 products launched over the last 18 months (ending Q1 FY 2026-2027) — contribute roughly $20-25 Mn to US sales, offsetting price erosion.
• Germany posted constant currency revenues of €29 Mn — down 9%, impacted by a supply disruption at a third-party supplier and lower tender off-take; a prominent supplier contributing 10-15% of German revenue is out of business.
• Germany remains the primary challenge — the company is still being outbid on tenders despite cost optimization efforts.

Supply Disruption Derails Rs.250 Cr Target; Market Share Still 36%

• Semaglutide combined market share (oral + injectable) of 36% in Q1 FY 2026-2027 — retained 94% oral market share in June despite a new entrant; Q1 sales of Rs.50 Cr.
• Previous annual run-rate guidance of Rs.200-250 Cr for FY 2026-2027 — Q1 trajectory was on track before a Rs.50 Cr supply disruption on injectable SKUs, making the original target unattainable; management will reassess after one more quarter.
• Alternate API source for injectable secured — all Semalix SKUs expected back by end of August 2026; no impact on oral or reusable SKUs.
• India market size estimated at Rs.700-800 Cr in the first year of launch (FY 2026-2027) — Torrent's own target had been Rs.250 Cr; market plateaued after initial ramp-up due to trial drop-offs, side effects, and overstocking; July 2026 traction already visible.
• Brazil semaglutide filing under ANVISA review — the regulator has recently approved five semaglutide products (four from one competitor) and is expediting approvals; management expects a decision "in months, not years".
• Management admits losing first-mover advantage in Brazil — but expects to capture double-digit market share based on historical strength in the chronic/cardiac diabetes segment.
• No concrete partnership for Brazil semaglutide — Sanjay Gupta confirmed it is theoretically possible to use another company's marketing authorization via distributor arrangements, but Torrent has not found a suitable partner; the delay is not related to Dr. Reddy's.

Base EBITDA Margin Guidance of 50bps Annual Improvement Maintained

• Base business gross margin improved to ~78% in Q1 FY 2026-2027 — from 76-76.5% in FY 2025-2026, driven by annual price increases, higher branded business contribution (rising to 76% from 74%), and positive forex effects.
• Base business EBITDA margin of 33.3% in Q1 FY 2026-2027 — up from 32.8% in the prior year, maintaining the guidance of at least 50 bps annual improvement.
• Sustainable base business gross margins of up to 77% for FY 2026-2027 — management stated the remainder is due to one-off factors; operating expenses rose ~22% YoY in Q1 FY 2026-2027, partly due to forex and typically higher Q1 branded spending.
• Full-year FY 2026-2027 margin guidance deferred — management will wait one more quarter until the combined entity (post-merger effective 8 July 2026) settles before providing updated margin guidance.
• JB Pharma EBITDA margin of 35% in Q1 FY 2026-2027 — management suggested cost synergy contribution can be estimated by comparing organic JB margin improvement vs. the prior year (FY 2025-2026).
• Capital allocation discipline maintained — management will wait at least 12-18 months before considering new acquisitions, with a preference for Indian targets and a net debt/EBITDA ceiling of 3x-3.5x.